TABLE 4.
Comparison of HPgV-1 and HPgV-2 prevalence rates using molecular and serological tools
| Group | Total no. (%) positive (RNA or antibody) |
P valuea | No. (%) RNA positive |
No. (%) RNA and anti-E2 positive/total no. anti-E2 positive |
No. (%) RNA and anti-E2 positive/total no. RNA positive |
P valuea | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| HPgV-1 | HPgV-2 | HPgV-1 | HPgV-2 | HPgV-1 | HPgV-2 | HPgV-1 | HPgV-2 | |||
| HCV infectedb (n = 726) | 354 (48.76) | 24 (3.31) | 0.0001 | 67 (9.23) | 11 (1.51) | 3/287 (1.04) | 11/24 (45.89) | 3/67 (4.47) | 11/11 (100.00) | 0.0001 |
| HCV antibody positive/RNA negative (n = 299) | 173 (57.86) | 3 (1.00) | 0.0001 | 15 (5.02) | 1 (0.33) | 1/158 (0.63) | 1/3 (33.33) | 1/15 (7.86) | 1/1 (100.00) | 0.1250 |
| HIV infected (n = 434) | 181 (41.71) | 0 (0.00) | 0.0001 | 51 (11.75) | 0 (0.00) | 2/130 (1.54) | 0/0 (0.00) | 2/51 (3.92) | 0/0 (0.00) | NA |
| HBV infected (n = 456) | 53 (11.62) | 3 (0.66) | 0.0001 | 8 (1.75) | 0 (0.00) | 2/45 (4.44) | 0/3 (0.00) | 2/8 (25.00) | 0/0 (0.00) | NA |
| Volunteer control (n = 416) | 55 (13.22) | 1 (0.24) | 0.0001 | 17 (4.09) | 0 (0.00) | 0/38 (0.00) | 0/1 (0.00) | 0/17 (0.00) | 0/0 (0.00) | NA |
| Total (n = (2,331) | 816 (35.00) | 31 (1.33) | 0.0001 | 158 (6.78) | 12 (0.51) | 8/658 (1.21) | 12/31 (38.71) | 8/158 (5.06) | 12/12 (100.00) | 0.0001 |
a
P values were determined using Fisher's exact test, comparing HPgV-1 and HPgV-2. NA, not applicable.
b
The group does not include the previously identified samples UC0125.US and ABT0239AN.US (HCV RNA positive only). Overall, of the 14 known HPgV-2 RNA-positive samples, 13 (92.86%) had detectable anti-E2 responses.